Lamellar Ichthyosis (LI) is a form of congenital ichthyosis that is caused by mutations in the TGM1 gene that encodes for the transglutaminase 1 (TG1) enzyme. Functional inactivation of TG1 could be due to mutations, deletion or insertions. In this study, we have screened 16 patients affected by LI and found six new mutations: two transition/transversion (R37G, V112A), two nonsense mutations and two putative splice site both leading to a premature stop codon. The mutations are localized in exons 2 (N-terminal domain), 5, 11 (central catalytic domain), and none is located in the two beta-barrel C-terminal domains. In conclusion, this study expands the current knowledge on TGM1 mutation spectrum, increasing the characterization of mutations would provide more accurate prenatal genetic counselling for parents at-risk individuals.
Lamellar Ichthyosis (LI) is a form of congenital ichthyosis that is caused by mutations in the TGM1 gene that encodes for the transglutaminase 1 (TG1) enzyme. Functional inactivation of TG1 could be due to mutations, deletion or insertions. In this study, we have screened 16 patients affected by LI and found six new mutations: two transition/transversion (R37G, V112A), two nonsense mutations and two putative splice site both leading to a premature stop codon. The mutations are localized in exons 2 (N-terminal domain), 5, 11 (central catalytic domain), and none is located in the two beta-barrel C-terminal domains. In conclusion, this study expands the current knowledge on TGM1 mutation spectrum, increasing the characterization of mutations would provide more accurate prenatal genetic counselling for parents at-risk individuals. The epidermis is a multi-layered, stratified epithelium that provides a physical barrier for the organism, protecting it from pathogens and dehydration. 1 The epidermis is continuously regenerated by terminally differentiated keratinocytes [2] [3] [4] [5] [6] [7] that migrate from the inner basal layer (proliferative compartment) to the outer cornified layer (terminal differentiated compartment): this process is known as cornification, or formation of the cornified envelope. This requires a complex balance between the proliferating compartment, the differentiation compartment and the cornified envelope, which exert its protective barrier function in the epidermis. In addition to this terminal differentiation, another type of cell death occurs in the skin, namely programmed cell death or apoptosis. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Apoptosis is a developmental remodelling programme and a defensive, organized self-destruction of the cell in reaction to severe damage.
In several genetic disorders, such as ichthyosis, the corneification process is altered due to mutations in key components of the keratinocyte differentiation machinery. Autosomal recessive congenital ichthyosis (ARCI) is a rare heterogeneous keratinization disorder of the skin. According to the results of the 'First Ichthyosis Consensus Conference' in Sorè ze in 2009, in which the nomenclature and classification of inherited ichthyoses has been revised, the disease is clinically and genetically identified including harlequin ichthyosis, lamellar ichthyosis (LI), non-bullous congenital ichthyosiformis and congenital ichthyosiformis. 23 Valquist 24 recently also speculated on a new umbrella term for ARCI disease represented by noticeable phenotypic changing in early childhood and mild, non-LI/non-EI skin symptoms remaining into adulthood.
There are seven loci associated to ARCI with five causative genes identified. 25 These genes code for transglutaminase 1 (TGM1), 26, 27 the adenosine triphosphate binding cassette 12A, 28, 29 lipoxygenases (ALOXE3, ALOX12B) 30 and ichtyin (ichtyin or NIPAL4). 31, 32 Patients with the most severe types of ichthyosis show a congenital hyperkeratosis with scales covering a large part of the body's surface. In the LI patients is often present at birth a collodion membrane, covering the neonate, and consisting of shiny taut skin that eventually dries and peels away, leading to the development of large, thick brown scales. Patients with LI can be either homozygous for single mutations or heterozygous for two different mutations at the same locus.
The first gene associated to the disease has been the TGM1 at chromosome 14q11.2. 33, 34 The TGM1 gene encodes transglutaminase 1 (TG1), which is a member of a class of enzymes that form Ne-(g-glutamyl)lysine or mono-or bis(g-glutamyl)spermidine isopeptide bond cross-links between proteins, and it is a calcium-dependent enzyme. 1, 35 The TG1 enzyme is synthesized as an 817 residue polypeptide (90 kDa) and is modified by myristoyl and palitoyl adducts near the N-terminus of the protein. It is expressed in the upper spinous and granular layers beneath the stratum corneum. TG1 is an enzyme important in the formation of the cornified cell envelope, responsible for barrier function in stratified squamous epithelia, by the cross-linking of a variety of structural proteins including desmosomal proteins, involucrin, the small proline-rich proteins, loricrin and trichohyalin. 1, [36] [37] [38] It is also reported to crosslink hydroxiceramide during the formation of cornified cell envelope, specifically, omegahydroxyceramides covalently linked by ester bonds to cornified envelope proteins, most abundantly to involucrin. 37 The native full-length TG1 protein is proteolysed at two sites during maturation and the three components remain associated in the active membrane-bound form. 38 The domain spanning from Met-1 to Met-109 represents the pro-peptide portion of the protein, at the end of which is located the most important cleavage site, its cleavage increase the activity of the enzyme 4100 times, respect to the full-length protein. 39 The three-dimensional computerized homology model of TG1, based on the factor XIIIa 40 crystal structure, revealed that the enzyme operate essentially as a dimer. Each monomer has four distinct domains: the amino-terminal b-sandwich domain (domain 1) from residues Met-109 to Phe-247, codified by exons 2, 3 and 4; the transamidation catalytic core domain (domain 2) from the Ile-255 to Pro-559 (containing the catalytic triade Cys-377; His 336; Asn-459) and two carboxy-terminal b-barrel domains, which include Glu-577 to Arg-687 (domain 3) and Leu-694 to Gly-800 (domain 4), respectively. Mutations in the TGM1 gene cause defect in the intercellular lipid layers in the stratum corneum, [41] [42] [43] 26, 27 leading to defective barrier function of the stratum corneum resulting in the ichthyosis phenotype seen in LI patients 44 and in the TG1 knockout mice. 45 The mutations so far described in the literature are mainly localized not only in the catalytic cysteine or in its surrounding region, but also in the N-terminal domain and in the interface between these two domains, suggesting a functional conformational change occurring during catalysis. Mutations in the two N-terminal beta-barrel domains are less frequent, but still present.
The typical clinical features of LI are large, dark grey or large brownish thick scales, covering the entire body surface, including the face. Palmoplantar keratoderma is frequently seen, whereas the hair and the teeth appear normal. Skin manifestations rarely improve with the age. Light microscopy of lesional skin from patients with TGM1-dependent LI show marked hyperkeratosis. The granular layer is normal or mildly increased in thickness. However, in the milder form of LI, the large, dark, lamellar scales can be seen only at the restricted body sites including the trunk, lower legs, upper arms and foreheads. Sometimes the skin on the face and the extremities appears normal and hyperkeratosis is not seen on either the palms or soles. In these milder forms, thin, white to grey scales are sometimes seen on the neck, the extremities and the rest of the body surface. 33 In this study, we have investigated 60 LI patients and families of Italian origin by mutation analysis of the complete coding sequences of TGM1 gene. We found 22 mutations, distributed in 17 patients (26% of the total LI patients investigated), among them, 6 novel and 15 previously described. Some of these mutations are well described and characterized and represent a wide spectrum of characteristic mutations found in LI associated to TG1.
Results
Clinical and genetic analysis. We have screened 60 patients that were diagnosed as LI. Large parts of the probands showed the classical LI phenotypes with large brown and thick scales covering the entire body surface, born as collodion baby (patient 1, 2, 3, 4, 6, 7, 8, 9, 8, 10, 11, 12, 13, 14, 15, 16, 17) , even if a wide gradient in disease severity had been observed, as described in Table 1 . The results of the genetics analysis in Ichthyosis patients are also represented in Table 1 . The sequence analysis of the TG1 patients showed the presence of new and known mutations in TGM1 gene in about 26% of them, thus confirming the heterogeneity of genetic inheritance of the disease. Regarding the mutations, they can be classified into three different subgroups: missense mutation leading to amino-acid substitutions, nonsense mutations causing the transition of a codifying codon into a stop codon and insertion/deletion mutations, that modify the reading frame of the coding region and/or the donor/acceptor splice sites. Regarding the new mutations found in homozygousity in patients (see below), they cannot be considered sporadic 'de novo' mutations, because there is no report of consanguinity in the family. Probably, the mutated alleles are present in very low frequency in the areas in which these patients reside. In the first group we found eight mutations caused by single-nucleotide transition/transversion, two of them are new mutations never described up to now. The new mutations found are: the R37G, found in patient 9 and located in exon 2, codifying for the pro-peptide region and the V112A found in patient 11 located at the beginning of the N-terminal beta-sandwich domain (Figure 1) Table 1 for further details. Among the nonsense mutations, we found four single-nucleotide transitions, all giving rise to stop codons and truncated proteins, the already known R54X (patient 2), R348X (patient 17), and the two new mutations W263X (patient 3) and S550X (patient 11). The first mutation, R54X truncates the enzyme in the second exon, presumably in this case there is the absence of a translation product due to the reduced size of the mRNA. In W263X mutant the enzyme ends at the level of exon 5, and the R348X in exon 7, both resulting in the loss of catalytic triade. The S550X mutants is also C-terminal truncated, it contains the active site but lacks the beta-barrel 1 and 2 domains, important for TG1 activity (Figure 1 ). In addition, in patient 9 we found an heterozygous mutation analysing the RNA. We discovered the deletion c.1465_1492del giving rise to the Y489X nonsense mutation again generating a truncated enzyme lacking the beta-barrel 1 and 2 domains. In patient 6, we also found a deletion mutation in the last 26 residues of intron 5 (c.851_877del), leading to the insertion of the residual part of the intron 5 in the coding sequence, resulting in the formation of a premature stop codon (Figure 1 ). It is interesting to note from this study that the most frequent mutation found in Italian IL patients bearing TG1 mutations is splicing error giving rise to intron insertion and consequent frame shift and premature stop codon formation (homozygous mutation in patients 12-16 and heterozygous mutation in patients 7). Mutations reported in the present study (novel) are in bold.
a All patients analysed were European, Caucasian race, except patient 9 (African).
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Conclusion
Several previous studies have attempted to demonstrate the existence of genotype-phenotype correlations between mutation in TG1 and clinical and/or ultra structural findings of the patient skins. However, there is a strong variability in clinical features of patients with the same mutation and there is not a clear association between the TG1 domain affected by the mutation and the severity of the phenotype. Our work, together with other studies, contribute to the identification of a large number of mutations with the aim to simplify the challenge in confirming the clinical diagnosis of patients affected by LI. Despite the genetic heterogeneity of this disease, TG1 has been the causative gene identified most often 25, 46 and consequently the first gene to be analysed to screen for mutations, expanding the mutations spectrum will facilitate the understanding of genetic, molecular and pathophysiological aspect of LI. In addition, although the mutations found are distributed along all the gene sequence, we can observe among italian patients a clear founder effect regarding the intron5/exon6 splice site mutation. Our results could enhance our understanding in the pathogenesis of icthyosis and will be useful for new therapeutic approach also for the phenotypic shifts of ARCI.
Materials and Methods
Collection of clinical material and DNA isolation. Genomic DNA samples were extracted from patient blood and from the other family members according to standard procedures. 50 This work was approved in the institutional ethics committee, at IDI-IRCCS, Istituto Dermopatico dell'Immacolata, Rome. The authors obtained informed consent from patients who provided their specimens.
PCR and RT-PCR amplification of TGM1 and DNA sequencing. Reverse transcription was performed using the Superscript-II reverse transcriptase (Life Technologies Ltd, Paisley, UK), with 100 ng of total RNA using 10 pmol of oligo dT primers, buffer and enzyme concentrations according to the manufacturer instructions. The entire coding region of the TGM1 gene was PCR amplified using 0.4 mM of primer 5 0 -CTCCCTCCCACATAAGTCAC-3 0 , for ( þ ) strand and 5 0 -TAG CATCTGTTCCCCCAGTGCAAGTGAAG-3 0 , for ( À ) strand, designed from the published cDNA sequences. PCR fragments were resolved on 0.8% agarose gel (TAE), extracted and purified using the Qiaex II extraction kit (Qiagen, Valencia, CA, USA). Approximately 100 ng of purified template DNA was automatically sequenced with the BigDye Termination Reaction Kit (Applied Biosystem, Carlsbad, CA, USA) on an ABI-PRISM 377 DNA sequencer (Applied Biosystem), using internal primers. In patients for whom the RNA was not available, the coding region has been amplified using intronic primers flanking exons.
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